- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03419533
Study to Assess Oropharyngeal Carriage of N. Meningitidis in South Australian School Leavers (B Part Of It)
An Observational Cross-sectional Study to Assess Oropharyngeal Carriage of N. Meningitidis in South Australian School Leavers
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
This carriage study of a cohort of school leavers in South Australia (SA) will provide an opportunity to assess carriage rates in the young adult population (school leavers) following introduction of a 4CMenB vaccination program in senior school students from 2017-2018.This will allow a comparison of carriage prevalence in the two years (2018 and 2019) following implementation of the school program to assess impact on carriage at a population level and compare carriage prevalence in vaccinated versus non-vaccinated groups. Assessment of any association between risk factors and prevalence of nasopharyngeal carriage in school leavers will be made and compared between vaccinated and unvaccinated students.
School leavers are defined as students who were enrolled in year 12 at school in the preceding year of recruitment and have been chosen as they are likely to have the highest carriage rates. A high proportion (approximately two thirds) of students will be immunised by the time of throat swab collection in years 2018 and 2019. Assessing carriage in both vaccinated and unvaccinated cohorts will further inform the effect of 4CMenB vaccine on carriage at a population level. This will help determine any herd immunity impact of 4CMenB vaccine and persistence of any effect.
Studietype
Inschrijving (Werkelijk)
Contacten en locaties
Studie Locaties
-
-
South Australia
-
Adelaide, South Australia, Australië, 5006
- Women's and Children's Hosptial
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- South Australian school leavers between 17 to 25 years of age (enrolled in year 12 in the previous year ie year 2018, students are eligible if they were enrolled in year 12 in 2017, year 2019, students are eligible if they were enrolled in year 12 in 2018).
Exclusion Criteria:
- No exclusion criteria
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Cohorten en interventies
Groep / Cohort |
|---|
|
2018 school leavers
South Australian school leavers in 2018 (year 12 in 2017)
|
|
2019 school leavers
South Australian school leavers in 2019 (year 12 in 2018)
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Estimate the Difference in Carriage Prevalence of Disease Associated Genogroups of N. Meningitidis (A, B, C, W, X, Y) Between School Leavers in 2018 (Year 12 in 2017) and 2019 (Year 12 in 2018), Following a 4CMenB School Immunisation Program
Tijdsspanne: 2018 to 2019
|
As measured by PCR in school leavers in 2018 and 2019
|
2018 to 2019
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Estimate the Difference in Carriage Prevalence of All N. Meningitidis Genogroups Between South Australian School Leavers in 2018 (Year 12 in 2017) and 2019 (Year 12 in 2018)
Tijdsspanne: 2018 to 2019
|
As measured by PCR in school leavers in 2018 and 2019
|
2018 to 2019
|
|
Estimate the Difference in Carriage Prevalence of Each N. Meningitidis Genogroup (A, B, C, W, X, Y) Between South Australian School Leavers in 2018 (Year 12 in 2017) and 2019 (Year 12 in 2018)
Tijdsspanne: 2018 to 2019
|
As measured by PCR in school leavers in 2018 and 2019
|
2018 to 2019
|
|
Across Years, Estimate the Difference in Carriage Prevalence of N. Meningitidis Genogroups Causing Disease (A, B, C, W, X, Y) Between South Australian School Leavers Who Received 4CMenB Vaccine and Unvaccinated Students
Tijdsspanne: 2018 to 2019
|
As measured by PCR in vaccinated and unvaccinated school leavers
|
2018 to 2019
|
|
Across Years, Estimate the Difference in Carriage Prevalence of All N. Meningitidis Genogroups Between South Australian School Leavers Who Have Received 4CMenB and Unvaccinated Students.
Tijdsspanne: 2018 to 2019
|
As measured by PCR in vaccinated and unvaccinated school leavers in 2018 and 2019
|
2018 to 2019
|
|
Across Years, Estimate the Difference in Each N. Meningitidis Genogroup (A, B, C, W, X, Y) Carriage Prevalence Between South Australian School Leavers Who Received 4CMenB Vaccine and Unvaccinated Students
Tijdsspanne: 2018 to 2019
|
As measured by PCR in vaccinated and unvaccinated school leavers
|
2018 to 2019
|
|
Identify Characteristics Associated With Carriage Prevalence of All N. Meningitidis Genogroups in South Australian School Leavers in 2018/2019
Tijdsspanne: 2018 to 2019
|
As measured by PCR in school leavers
|
2018 to 2019
|
|
Identify Characteristics Associated With Carriage Prevalence of N. Meningitidis Genogroups Causing Disease (A, B, C, W, X, Y) in South Australian School Leavers in 2018 /2019
Tijdsspanne: 2018 to 2019
|
As measured by PCR in school leavers
|
2018 to 2019
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Describe Carriage Density of N. Meningitidis Genogroups as Measured by qPCR in School Leavers
Tijdsspanne: 2018 to 2019
|
Density of N. meningitides by qPCR
|
2018 to 2019
|
|
Describe Genome Sequencing of Pathogenic N. Meningitidis (A, B, C, W, X, Y) in Carriage Among School Leavers.
Tijdsspanne: 2018 to 2019
|
Whole genome sequencing of N. meningitidis
|
2018 to 2019
|
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Algemene publicaties
- Marshall HS, McMillan M, Koehler A, Lawrence A, MacLennan J, Maiden M, Ramsay M, Ladhani SN, Trotter C, Borrow R, Finn A, Sullivan T, Richmond P, Kahler C, Whelan J, Vadivelu K. B Part of It School Leaver protocol: an observational repeat cross-sectional study to assess the impact of a meningococcal serogroup B (4CMenB) vaccine programme on carriage of Neisseria meningitidis. BMJ Open. 2019 May 6;9(5):e027233. doi: 10.1136/bmjopen-2018-027233.
- McMillan M, Bednarz J, Leong LEX, Lawrence A, Marshall HS. Impact of COVID-19 Containment Strategies and Meningococcal Conjugate ACWY Vaccination on Meningococcal Carriage in Adolescents. Pediatr Infect Dis J. 2022 Nov 1;41(11):e468-e474. doi: 10.1097/INF.0000000000003660. Epub 2022 Jul 27.
- McMillan M, Koehler AP, Lawrence A, Sullivan TR, Bednarz J, MacLennan JM, Maiden MCJ, Ladhani SN, Ramsay ME, Trotter C, Borrow R, Finn A, Kahler CM, Whelan J, Vadivelu K, Richmond PC, Marshall HS. B Part of It School Leaver Study: A Repeat Cross-Sectional Study to Assess the Impact of Increasing Coverage With Meningococcal B (4CMenB) Vaccine on Carriage of Neisseria meningitidis. J Infect Dis. 2022 Feb 15;225(4):637-649. doi: 10.1093/infdis/jiab444.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Andere studie-ID-nummers
- HREC/16/WCHN/140_3
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Neisseria Meningitidis
-
Emory UniversityPfizerWervingNeisseria MeningitidisVerenigde Staten
-
PfizerVoltooid
-
University Hospital, RouenInstitut Pasteur; Direction Générale de la Santé, FranceVoltooid
-
Public Health EnglandVoltooid
-
Shanghai Yuguan Biotech Co., Ltd.(Delonix Bioworks)WervingNeisseria meningitidis serogroep BAustralië
-
Public Health EnglandVoltooidNeisseria meningitidis serogroep BVerenigd Koninkrijk
-
Sanofi Pasteur, a Sanofi CompanyVoltooidVirusziekten | Bacteriële infecties | Neisseria MeningitidisFinland
-
MCM Vaccines B.V.Merck Sharp & Dohme LLC; Sanofi Pasteur, a Sanofi CompanyVoltooidVirusziekten | Bacteriële infecties | Neisseria Meningitidis
-
GlaxoSmithKlineVoltooidNeisseria Meningitidis | Haemophilus Influenzae type bAustralië
-
GlaxoSmithKlineVoltooidNeisseria Meningitidis | Haemophilus Influenzae type bVerenigd Koninkrijk